- Pregnancy-specific metabolic adaptations substantially alter drug pharmacokinetics and pharmacodynamics, influencing maternal and fetal drug exposure and therapeutic response.
- Obstetric pharmacometabolomics uses endogenous metabolic signatures to investigate, predict and monitor medication response in pregnancy across drugs and obstetric conditions.
- Clinical implementation requires longitudinal studies, standardised biospecimen protocols, rigorous exposure assessment, validated biomarkers, diverse populations and integration with other omics and modelling.
Future Sci OA. 2026 Dec;12(1):2757077. doi: 10.1080/20565623.2026.2757077. Epub 2026 Nov 6.
ABSTRACT
INTRODUCTION: Pregnancy-related physiologic and metabolic changes influence drug exposure and response. Yet therapeutic decisions often lack individualized biologic guidance. Obstetric pharmacometabolomics uses endogenous metabolic signatures to investigate and potentially predict and monitor drug response in pregnancy.
AREAS COVERED: PubMed/MEDLINE and Google Scholar were searched from inception through October 12, 2026, using terms related to metabolomics, pharmacometabolomics, medication exposure, treatment response, maternal-placental-fetal metabolism, pharmacokinetics, pharmacodynamics, and obstetric medications. Human pregnancy studies, longitudinal investigations, drug-perturbation experiments, and mechanistic preclinical studies were prioritized. This review examines pregnancy-specific metabolic adaptations, analytical approaches, and potential applications involving aspirin, antihypertensives, antidiabetic therapies, antiretrovirals, antimicrobials, corticosteroids, and psychiatric medications. It also considers pharmacometabolic approaches to preeclampsia, gestational diabetes mellitus, preterm birth, fetal growth disorders, obesity, and HIV-associated pregnancy.
EXPERT OPINION: Obstetric pharmacometabolomics offers a promising framework for individualized therapeutics, but clinical implementation requires longitudinal studies, standardized biospecimen collection, rigorous exposure assessment, validated biomarkers, and diverse populations. Integration with pharmacogenomics, pharmacomicrobiomics, pharmacoproteomics, and model-informed drug development can improve therapeutic precision, provided that clinical utility is demonstrated.
PMID:42992985 | DOI:10.1080/20565623.2026.2757077
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

